Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:51:44.247Z.
Calculation as of: 2026-10-06T19:51:44.247Z.
Quote observation: 2026-10-06T19:50:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a9a1b17caad0ab37430e79e816a911291535ac0fb348029df9f580b63ef335
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Cadrenal Therapeutics, Inc. Common Stock
Market Cap
$3.57M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $3.57M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.61M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.64M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.66M | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.46M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.31M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.87M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
